Welcome to LLUSCBA


FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer

05/04/2018 1:27 PM | Bo Burge

The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive). 

The Laredo Licensed U.S. Customs Brokers Association, Inc. Laredo, TX 78040--Copyright © 2018 All Rights Reserved

Powered by Wild Apricot Membership Software